Kyorin Pharmaceutical has formulated a new mid-term management plan ‘Vision 110 \uff0dStage2\uff0d’ for FY2026\u2013FY2029. The revenue target is over 120 billion yen, operating profit over 17 billion yen, and ROE of 5% or more.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4569","jir_company_name":"Kyorin Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4569-20260512-05.pdf","jir_short_summary":"Kyorin Pharmaceutical has formulated a new mid-term management plan 'Vision 110 \uff0dStage2\uff0d' for FY2026\u2013FY2029. The revenue target is over 120 billion yen, operating profit over 17 billion yen, and ROE of 5% or more.","jir_summary":"### Overview of the Mid-Term Management Plan 'Vision 110 \uff0dStage2\uff0d'\nKyorin Pharmaceutical has developed the mid-term management plan 'Vision 110 \uff0dStage2\uff0d' covering FY2026 to FY2029, as the second phase of its long-term vision 'Vision 110' toward its 110th anniversary. The basic policy emphasizes active investment for sustainable growth, with priority given to acquiring in-licensed products. The plan promotes five strategic initiatives (expanding development pipeline, strengthening new drug creation, maximizing the diffusion of new drugs, advancing health-related businesses, and establishing a sustainable corporate foundation), aiming to achieve performance goals and enhance stakeholder evaluations.\n\n### Performance Goals and Shareholder Return Policy\nThe revenue target for FY2029 is over 120 billion yen, with an operating profit (before R&D expenses deduction) of over 17 billion yen and an ROE of 5% or more. Additionally, for FY2032, the goal is to achieve a revenue of over 160 billion yen, operating profit of over 20 billion yen, and an ROE of 8% or more as the Stage3 exit target. Regarding shareholder returns, the company prioritizes investment for sustainable growth beyond Stage3 while maintaining a dividend of 25 yen per share annually, and plans to consider dividend increases.","jir_financial_highlights":"Net Sales: Over 120 billion yen (FY2029 Stage2 Exit Target) (FY2025 actual: 126.3 billion yen)\nOperating Income (before R&D expenses deduction): Over 17 billion yen (FY2029 Stage2 Exit Target) (FY2025 actual: 15.6 billion yen)\nROE: 5% or more (FY2029 Stage2 Exit Target) (FY2025 actual: 2.5%)\nDividend per Share: 25 yen\/year (Goals beyond Stage3) (Unknown)","jir_category":"","jir_hashtags":"#KyorinPharmaceutical, #MidTermManagementPlan, #Vision110, #BusinessStrategy","jir_key_figures":"Revenue target (FY2029 Stage2 exit): over 120 billion yen\nOperating profit target (FY2029 Stage2 exit): over 17 billion yen\nROE target (FY2029 Stage2 exit): 5% or more","jir_meta_title":"\u3010Kyorin Pharmaceutical\u3011Formulation of FY2026\u2013FY2029 Mid-Term Management Plan | Revenue Over 120 Billion Yen Goal","jir_meta_description":"Kyorin Pharmaceutical has formulated the mid-term management plan 'Vision 110 \uff0dStage2\uff0d' covering FY2026 to FY2029, aiming for over 120 billion yen in revenue, over 17 billion yen in operating profit, and an ROE of 5% or more.","jir_og_title":"\u3010Kyorin Pharmaceutical\u3011FY2026\u2013FY2029 Mid-Term Management Plan | Revenue Over 120 Billion Yen Goal","jir_og_description":"Kyorin Pharmaceutical announces its new mid-term management plan 'Vision 110 \uff0dStage2\uff0d.' The plan aims for sustainable growth through active investments and new drug creation.","jir_og_image_url":"\/assets\/og\/company-business_update.jpg","jir_chart_data_collection":"[]","ir_related_company":16660,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-48160","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n